Limitations of Current Evidence Several significant limitations in the current evidence base warrant acknowledgment: Population Diversity : Most major trials have been conducted in predominantly white, well-resourced populations, potentially limiting generalizability to more diverse demographic groups where obesity prevalence is often highest
In agreement with this evidence, Fujishima et al., demonstrated that Liraglutide improved visceral fat adiposity, produced meaningful weight loss, and significantly improved eating behavior in obese Japanese patients with type 2 diabetes
Combining medication with therapy is highly effective for a comprehensive approach to improve long-term outcomes
How Nausea Changes as Your Body Adapts to Semaglutide Tolerance to semaglutide-induced nausea builds gradually over your first four to eight weeks of treatment
Always consult with a qualified healthcare provider before starting, stopping, or changing any treatment